为什么韩国医疗技术交易要看产品路径？
韩国医疗器械、诊断、数字健康、美容医疗设备和医疗软件企业可能具备研发速度和亚洲渠道能力。中国买方可通过收购获得产品和区域增长机会。
但产品监管路径和质量体系必须优先确认。
估值重点
买方应关注监管状态、临床证据、毛利率、渠道、知识产权、研发管线、质量体系和团队留任。
尽职调查重点
尽调应覆盖技术文件、质量体系、召回和投诉、经销商合同、产品责任、知识产权、数据合规、税务和员工。
Lyndon如何协助
Lyndon可协助中国买方、韩国医疗技术企业和顾问准备估值、资料室、监管风险清单和交易执行。
About the Author
Daniel Bae
Co-founder & CEO, Lyndon Advisory
Daniel is an investment banker with 15+ years of experience in M&A, having advised on deals worth over US$30 billion. His career spans Citi, Moelis, Nomura, and ANZ across London, Hong Kong, and Sydney. He holds a combined Commerce/Law degree from the University of New South Wales. Daniel founded Lyndon Advisory to solve the pain points in M&A, enabling bankers to focus on what matters most — delivering trusted advice to clients.
About Lyndon Advisory
Lyndon Advisory is an M&A advisory firm built for Asia Pacific. We help business owners sell their companies and investors make strategic acquisitions with senior-led execution, disciplined process management, and AI-supported buyer intelligence.
Learn about selling your business